A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor ... of blood pressure and adjustment of antihypertensive medications ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

Few drugs have ... and high blood sugar levels cause damage to the lining of your blood vessel. Ozempic may also act directly on the cardiovascular system. There are GLP-1 receptors in blood ...

Popular GLP-1 medications approved for weight loss ... compared with people taking other medications to manage their blood sugar.